Shots:
- Samsung Bioepis & NIPRO have entered into a license, development & commercialization agreement for various biosimilar candidates, incl. SB17, a biosimilar version of Stelara (ustekinumab) in Japan
- As per the deal, NIPRO will be responsible for commercialization of the biosimilar candidates in Japan, with Samsung Bioepis handling development, manufacturing & supply activities
- Ustekinumab is a fully human anti-IL-12/IL-23 mAb indicated for the treatment of autoimmune diseases incl. plaque psoriasis, psoriatic arthritis & Crohn’s disease
Ref: Businesswire | Image: Samsung Bioepis | Press Release
Related News:- Samsung Bioepis and Organon’s Hadlima (Biosimilar, Humira) Receives the US FDA’s Interchangeability Designation for All Presentations
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
